Global healthcare technology leader Medtronic has announced its definitive agreement to acquire SPR Therapeutics for approximately $650 million. This strategic acquisition will integrate SPR's innovative temporary peripheral nerve stimulation (PNS) technology into Medtronic's extensive neuromodulation portfolio. The deal aims to provide earlier, minimally invasive pain relief options for the millions of adults suffering from chronic pain.
Strategic Expansion in Pain Management
This acquisition leverages Medtronic's five decades of leadership in neuromodulation and expands its comprehensive pain therapy offerings. By incorporating SPR's technology, Medtronic can support patients earlier in their care continuum with complementary treatment options. The move aligns with the company's strategy of strengthening its core franchises through targeted acquisitions.
Chronic pain is a significant health issue, affecting nearly 50 million adults in the United States alone. SPR Therapeutics addresses this with its FDA-cleared SPRINT PNS System, a unique 60-day therapy for pain relief. This approach provides a temporary treatment that does not require a permanent implant, fitting seamlessly into existing clinical workflows.
The Growing PNS Market and Clinical Validation
The market for peripheral nerve stimulation is experiencing substantial growth, creating a favorable environment for this acquisition. This expansion is fueled by mounting clinical evidence, improving reimbursement policies, and a strong patient demand for non-opioid therapies. Medtronic is now well-positioned to lead in this expanding segment of pain management.
The effectiveness of the SPRINT PNS System is supported by significant real-world data. The largest retrospective review to date, involving over 6,100 patients, demonstrated impressive results for the technology. Over 71 percent of participants reported significant pain relief or an improved quality of life after the 60-day treatment.
Leadership Perspectives on the Acquisition
Domenico De Paolis, Interim President of Neuromodulation at Medtronic, emphasized the company's patient-first mission. He stated that adding temporary PNS broadens access to neuromodulation and supports patients across more stages of their pain journey. This minimally invasive therapy represents a thoughtful expansion of Medtronic's pain intervention solutions.
Maria E. Bennett, President and CEO of SPR Therapeutics, described the agreement as a pivotal step forward for patient-centered innovation. She expressed confidence that the partnership with Medtronic will help reach more patients in need of relief. Together, the companies aim to help individuals reclaim their lives from chronic pain.
Transaction Details and Future Outlook
The transaction is structured as an upfront cash payment of approximately $650 million for all outstanding equity in SPR. Finalization of the deal is contingent upon customary closing conditions and the necessary regulatory approvals. Both parties are working towards a smooth and efficient closing process.
The acquisition is anticipated to close within the first half of Medtronic's Fiscal Year 2027, which began on April 25, 2026. Until the transaction is officially completed, Medtronic and SPR Therapeutics will continue to function as separate and independent entities. This ensures operational continuity during the transition period.
Medtronic's acquisition of SPR Therapeutics marks a significant investment in advancing non-opioid chronic pain management solutions. The integration of the SPRINT PNS System will enhance Medtronic's portfolio, offering a clinically validated, minimally invasive option for patients. This strategic move positions the company to better address a widespread health issue and improve the quality of life for many.